




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Review

Insights into the antiviral activity of phospholipases A₂ (PLA₂s) from snake venoms

S.C. Teixeira^a, B.C. Borges^a, V.Q. Oliveira^b, L.S. Carregosa^b, L.A. Bastos^b, I.A. Santos^c, A.C.G. Jardim^c, F.F. Melo^b, L.M. Freitas^b, V.M. Rodrigues^{d,*}, D.S. Lopes^{b,e,*}

^a Department of Immunology, Institute of Biomedical Science, Federal University of Uberlândia, Uberlândia, MG, Brazil

^b Multidisciplinary Institute of Health, Anísio Teixeira Campus, Federal University of Bahia, Vitória da Conquista, BA, Brazil

^c Laboratory of Virology, Institute of Biomedical Science, Federal University of Uberlândia, Uberlândia, MG, Brazil

^d Laboratory of Biochemistry and Animal Toxins, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil

^e Institute of Health Sciences, Department of Bio-Function, Federal University of Bahia, Salvador, BA, Brazil

ARTICLE INFO

Article history:

Received 27 May 2020

Received in revised form 8 July 2020

Accepted 14 July 2020

Available online 19 July 2020

Keywords:

Snake venom

Phospholipases A₂

Virus

Antiviral drugs

ABSTRACT

Viruses are associated with several human diseases that infect a large number of individuals, hence directly affecting global health and economy. Owing to the lack of efficient vaccines, antiviral therapy and emerging resistance strains, many viruses are considered as a potential threat to public health. Therefore, researches have been developed to identify new drug candidates for future treatments. Among them, antiviral research based on natural molecules is a promising approach. Phospholipases A₂ (PLA₂s) isolated from snake venom have shown significant antiviral activity against some viruses such as Dengue virus, Human Immunodeficiency virus, Hepatitis C virus and Yellow fever virus, and have emerged as an attractive alternative strategy for the development of novel antiviral therapy. Thus, this review provides an overview of remarkable findings involving PLA₂s from snake venom that possess antiviral activity, and discusses the mechanisms of action mediated by PLA₂s against different stages of virus replication cycle. Additionally, molecular docking simulations were performed by interacting between phospholipids from Dengue virus envelope and PLA₂s from *Bothrops asper* snake venom. Studies on snake venom PLA₂s highlight the potential use of these proteins for the development of broad-spectrum antiviral drugs.

© 2020 Published by Elsevier B.V.

Contents

1. Viral diseases: a public health problem	616
2. Phospholipases A ₂ from snake venom	617
3. sPLA ₂ s from snake venom with antiviral effects	619
3.1. Crotoxin, PLA ₂ -CB (basic chain of crotoxin) and PLA ₂ -IC from <i>Crotalus durissus terrificus</i> venom.	619
3.2. BIK-PLA ₂ and BID-PLA ₂ from <i>Bothrops leucurus</i> venom	619
3.3. Mt-I and Mt-II from <i>Bothrops asper</i> venom	619
3.4. Taipoxin (<i>Oxyuranus scutellatus</i>), nigexine (<i>Naja nigricollis</i>) and Nmm _{CMIII} (<i>Naja mossambica mossambica</i>).	620
3.5. CM-II-sPLA ₂ from <i>Naja mossambica mossambica</i> venom.	620
4. Proposed antiviral mechanism of sPLA ₂ s from snake venom	620
5. Concluding remarks: sPLA ₂ s as a possible useful tool for the development of antiviral compounds.	622
Acknowledgements	622
References.	622

* Corresponding authors at: Multidisciplinary Institute of Health, Federal University of Bahia, Anísio Teixeira Campus, Vitória da Conquista-BA, Brazil.

E-mail addresses: veridiana@ufu.br (V.M. Rodrigues), lsdaiana@yahoo.com.br, lsdaiana@ufba.br (D.S. Lopes).

1. Viral diseases: a public health problem

Viruses are associated to several endemic diseases, including Enterovirus [1], HPV (Human papillomavirus) [2], HIV (Human immunodeficiency virus) [3] and HSV (Herpes simplex virus) [4], as well as in outbreaks as Ebola virus, ZIKV (Zika virus), Influenza virus, YFV (Yellow Fever virus), DENV (Dengue virus) and, currently, the SARS-CoV-2 (Severe Acute Respiratory Coronavirus 2) [5–9]. Most of the reported outbreaks since 1980 were related to virus infections [10], which are still a global burden for public health and economy. In addition, due to their genetic diversity, viruses are able to infect a wide range of hosts that can result in host jumps after zoonotic contacts [11,12].

Pandemics caused by viruses are usually severe and can claim up to million lives, as shown during the pandemic of H1N1 in 1918 [13], H1N1 'swine flu' in 2009 [14] and Coronavirus Disease 2019 (COVID-19) [15], that infected 4,993,470 people and caused 327,738 deaths until May 22, 2020 in worldwide according to World Health Organization. Furthermore, the global incidence of dengue has grown dramatically in recent decades. It is estimated that 100 to 400 million cases of dengue occur annually worldwide [16].

Viral infection depends on the successful replication into the host cells [17,18]. In general, the replicative cycle starts by the viral particle attaching to specific receptors in the surface of host cells that triggers the viral entry by endocytosis (non-enveloped or enveloped virus), membrane fusion (enveloped virus) and direct penetration [19–21]. After internalization, the capsid is released into the cytoplasm, allowing viral genome uncoating [22], which is replicated to produce copies of the genome and translated to viral proteins. In the endoplasmic reticulum (ER) and Golgi complex, the viral structure is assembled, matured and then forwarded to host cell membrane, where the progeny of virus particles is released [23].

Currently, specific antiviral drugs and vaccines are not sufficient to control emerging and reemerging viral diseases [24,25]. Thus, the discovery of novel antiviral drugs is mandatory. In general, antiviral therapy is the only approach to specifically treat viral infections, abrogating viral replicative cycle [26]. However, due to the high genetic variability, viruses can rapidly acquire resistance to antiviral treatment, especially RNA viruses [27–29]. Furthermore, antiviral therapy and the prolonged treatment can cause several adverse effects, including gastrointestinal effects, fatigue, headache, neuropathy and liver toxicity [30–32]. In addition, there are no antivirals to all diseases and the only course is supportive therapy and, thereby, numerous innovative drugs have been developed from natural prototypes such as aspirin (anti-inflammatory) and morphine (analgesic) [33].

In this way, a diversity of compounds isolated from natural sources has set grounds for further advances in drug development against various diseases [34]. Among them, many drugs based on snake venoms were approved by the FDA or are involved in preclinical or clinical trials for a variety of therapeutic applications [35–39]. The development of snake venom-derived drugs gained a significant improve since the discovery of bradykinin-potentiating peptides (BPP) isolated from the Brazilian arrowhead viper (*Bothrops jararaca*) venom, which allowed the development of captopril, an inhibitor of the angiotensin-converting enzyme that is widely used against hypertensive process [40,41]. Besides that, other snake venom-derived drugs have been found in clinical use, such as tirofiban and eptifibatid (antiplatelet agents) [42,43], batroxobin, moojenin and vivostat (anticoagulant agents) [44–47]. Other drugs which comprise molecules from snake venom as scaffolds are also being explored in preclinical studies [48].

Due to this therapeutic potential, snake venom toxins have been widely explored for the discovery of new bioactive compounds and stand out as an alternative source for therapeutics for a variety of diseases, including life-threatening viral illnesses [49–52].

2. Phospholipases A₂ from snake venom

Phospholipases (EC 3.1.) family is widely distributed in nature and includes hydrolase enzymes, which are essential for phospholipid metabolism and for the regulation of membrane lipids, membrane composition, signaling, digestion, and inflammation [53]. These proteins are classified into four major families (A, B, C and D) based on the site cleaved in the phospholipid molecule [54,55].

Among phospholipases family, the Phospholipases A₂ (PLA₂s) are the most studied group [53,54]. These enzymes hydrolyze 2-acyl ester bond to 2-sn phospholipids, releasing free fatty acid and lysophospholipids [56,57]. The free fatty acids (arachidonic acid) can be converted into eicosanoids (prostaglandins, thromboxanes, prostacyclins and leukotrienes), which are associated to a range of physiological and pathological effects, such as inflammation and platelet activation. In addition, the lysophospholipids are also related to a variety of physiological roles in cell signaling [53,58].

PLA₂s are classified into six groups: cytosolic (cPLA₂), Ca⁽²⁺⁾-independent (iPLA₂), platelet-activating factor acetylhydrolase (PAF-AH), lysosomal PLA₂ (LyPLA₂), adipose specific PLA₂ (AdPLA₂) and secretory PLA₂ (sPLA₂) [53]. In addition, the sPLA₂s are divided into the following groups: IA, IB, IIA, IIB, IIC, IID, IIE, IIF, III, V, IX, X, XIA, XIB, XII, XIII and XIV [53,54]. PLA₂s from snake venom belong to the group of secreted type of enzymes (sPLA₂s) and can be classified into the structural group IB (in Elapidae snake venoms), which exhibits homology to the mammalian pancreatic juice PLA₂, and also into the group IIA (in Viperidae snake venoms), that is homologous to the mammalian 'inflammatory' PLA₂ [59]. Although the PLA₂s family is more frequent in snake venom, recent proteome studies have demonstrated that Phospholipases B (PLB) can also be found in snake venom [60–62].

sPLA₂s are proteins with molecular mass of about 14 kDa, pH optimum at 7 and share a conserved catalytic mechanism based on a His/Asp dyad using Ca²⁺ as an essential cofactor for the catalytic activity. Group II of sPLA₂s presents an extended C-terminal segment (5–7 amino acids) [63,64] and is subdivided into two main subgroups, depending on the amino acid residue at position 49 in the protein primary structure. Aspartate (Asp49 or D49) sPLA₂s are enzymatically active, while lysine (Lys49 or K49) sPLA₂s present no enzymatic activity [65–67]. However, there are further variants, as the serine (Ser49), asparagine (Asn49) or arginine (Arg49) [68–70].

Lys49 PLA₂s are devoid of catalytic activity due to their inability to bind Ca²⁺, a key cofactor for PLA₂ activity. Although the lack of enzymatic activity, the Lys49 PLA₂ homologues have shown to display toxicity, especially myotoxicity [67]. The toxicity of Lys49 proteins can be related to a cluster of cationic and hydrophobic/aromatic amino acid residues located at the C-terminal region of these toxins [71,72].

Therefore, the cytotoxicity of sPLA₂ is probably mediated by the interaction between the C-terminal region and the plasma membrane [73,74]. Moreover, the PLA₂ effects can be mediated through the integrins and other receptors, such as vascular endothelial growth factor receptor-2 (VEGFR-2), and M-Type receptors [75–77]. Recently, it was demonstrated that the cell surface nucleolin interacts with and internalizes the PLA₂-like *Bothrops asper* myotoxin-II, which is responsible to mediate its toxic activity [78].

sPLA₂s from snake venom can act on cell membranes of specific tissues inducing several pharmacological actions such as myotoxicity, neurotoxicity, cardiotoxicity, platelet aggregation activation or inhibition, hypotension, edema among others [57,79]. In this scenario, these proteins have emerged as a potential therapeutic model, since numerous studies have focused on their microbicidal [80], antitumor [81–83], antiangiogenesis [84], antiparasitic [85–87] and antiviral activities [51].

The development of efficient antiviral therapies has become a global health emergency. In this sense, several researches have demonstrated

the antiviral activity of sPLA₂s from snake venom against human viruses, including DENV, YFV, HCV and others [88–92]. Hence, the present review aimed to summarize the sPLA₂s from snake venom that were

previously described to possess antiviral activity, highlighting the mechanisms of action of sPLA₂s against different stages of virus replication cycle (Table 1).

Table 1
sPLA₂s from snake venom with antiviral effects.

Source/species	Protein name	EC50/used dosage	Virus	Proposed action mechanism (inhibition)	Reference	
<i>Bothrops asper</i>	Mt-I	50 µg/mL	DENV-1, 2, 3	Entry (virucidal activity)	[92]	
		50 µg/mL 1.5 ng/mL (EC50)	YFV DENV-2			
<i>Bothrops jararacussu</i>	BthTX-I	50 µg/mL	DENV-1, 2, 3	Entry (virucidal activity)	[88]	
		50 µg/mL	YFV			
		2768 ng/mL (EC50)	DENV-2			
		4.8 ng/µL (EC50)	DENV-2			
		7.063 ng/µL (EC50)	YFV			
<i>Bothrops leucurus</i>	BIK-PLA ₂	57.3 ng/µL (EC50)	DENV-2	Entry	[91]	
		25.0 ng/µL (EC50)	YFV	(interfering in adsorption)		
<i>Crotalus durissus terrificus</i>	BID-PLA ₂	69.0 ng/µL (EC50)	DENV-2	Entry	[88–90,97]	
		23.4 ng/µL (EC50)	YFV	(interfering in internalization)		
<i>Crotalus durissus terrificus</i>	Crotoxin	20 µg/mL	DENV-1, 2, 3	Replication	[88–90]	
		20 µg/mL	DENV-2	(interfering in host cell components)		
		0.001 ng/µL (EC50)	DENV-2	Entry		
		0.00045 ng/µL (EC50)	YFV	(virucidal activity)		
		0.0046 ng/µL (EC50)	ROCV			
		0.0036 ng/µL (EC50)	MAYV			
		0.0054 ng/µL (EC50)	OROV			
		–	HIV-1,2			
		10 µg/mL	HCV			
		0.018 ng/µL (EC50)	DENV-2	Entry		
		0.0365 ng/µL (EC50)	YFV	(interfering in adsorption)		
		34.4 ng/µL (EC50)	DENV-2	Entry		
		13.7 ng/µL (EC50)	YFV	(interfering in internalization)		
		0.05 ng/µL (EC50)	DENV-2	Replication		
		0.04 ng/µL (EC50)	YFV	(interfering in host cell components)		
		10 µg/mL	HCV	Release		
		0.00003 ng/µL (EC50)	DENV-2	Entry		
		0.0037 ng/µL (EC50)	YFV	(virucidal activity)		
		0.021 ng/µL (EC50)	ROCV			
		0.066 ng/µL (EC50)	MAYV			
		0.0067 ng/µL (EC50)	OROV			
		10 µg/mL	HCV			
		0.044 ng/µL (EC50)	DENV-2	Entry		
		0.01647 ng/µL (EC50)	YFV	(interfering in adsorption)		
17.2 ng/µL (EC50)	DENV-2	Entry				
3.3 ng/µL (EC50)	YFV	(interfering in internalization)				
10 µg/mL	HCV					
10 µg/mL	HCV	Entry				
		(interfering in host cell components)				
		Replication				
		(interfering in host cell components)				
<i>Naja mossambica mossambica</i>	PLA ₂ -CB (subunit of crotoxin)	0.06 ng/µL (EC50)	DENV-2	Entry	[88]	
		0.26 ng/µL (EC50)	YFV	(virucidal activity)		
		6.08 µg/mL (EC50)	HCV			
		0.0137 ng/µL (EC50)	DENV-2	Entry		
		0.0054 ng/µL (EC50)	YFV	(virucidal activity)		
		0.133 ng/µL (EC50)	DENV-2	Entry		
		0.268 ng/µL (EC50)	YFV	(interfering in adsorption)		
		21.6 ng/µL (EC50)	DENV-2	Entry (interfering in internalization)		
		0.775 ng/µL (EC50)	DENV-2	Replication		
		1.30 ng/µL (EC50)	YFV	(interfering in host cell components)		
		0.036 ng/mL (EC50)	HCV	Entry		
		0.031 ng/mL (EC50)	DENV	(virucidal activity)		
<i>Naja mossambica mossambica</i>	CM-II-sPLA ₂	1.34 ng/mL (EC50)	JEV	Entry (virucidal activity)	[114]	
		10,000 ng/mL (EC50)	MERS-CoV			
		>10,000 ng/mL (EC50)	SINV			
		>10,000 ng/mL (EC50)	FLUAV			
		>10,000 ng/mL (EC50)	SeV			
		2300 ng/mL (EC50)	VSNJV			
		5.4 ng/mL (EC50)	HIV-1			
		>10,000 ng/mL (EC50)	HSV-1			
		>10,000 ng/mL (EC50)	CV-B3			
		>10,000 ng/mL (EC50)	EMCV			
		0.4 nM (EC50)	HIV-1 isolates			Entry
		0.4 nM (EC50)	HIV-1 isolates			(interfering in host cell components)
0.8 nM (EC50)	HIV-1 isolates					
<i>Naja nigricollis</i>	Nmm _{CMIII}	0.4 nM (EC50)	HIV-1 isolates	Entry	[107]	
<i>Oxyuranus scutellatus</i>	Nigexine	0.4 nM (EC50)	HIV-1 isolates	(interfering in host cell components)		
	Taipoxin	0.8 nM (EC50)	HIV-1 isolates			

CV-B3 (Coxsackievirus B3; Picornaviridae); DENV (Dengue virus); EMCV (Encephalomyocarditis virus; Picornaviridae); FLUAV (Influenza A virus); HCV (Hepatitis C virus); HIV (Human immunodeficiency virus); HSV (Herpes simplex virus); JEV (Japanese encephalitis virus); MAYV (Mayaro virus); MERS-CoV (Middle East respiratory syndrome coronavirus); OROV (Oropouche virus); ROCV (Rocio virus); SeV (Sendai virus); SINV (Sindbis virus); VSNJV (Vesicular stomatitis New Jersey virus); YFV (Yellow Fever virus).

3. sPLA₂s from snake venom with antiviral effects

3.1. Crotoxin, PLA₂-CB (basic chain of crotoxin) and PLA₂-IC from *Crotalus durissus terrificus* venom

The venom of *Crotalus durissus terrificus* (*C. d. terrificus*), a South American rattlesnake, is composed by a large number of molecules with biological activities, such as crotoxin, crotamin, PLA₂ “inter-cro” (PLA₂-IC), convulxin and gyroxin [93,94]. Crotoxin, which comprehends more than a half of the dry weight of *C. d. terrificus* venom, is a heterodimeric compound composed by the PLA₂-CB (a basic phospholipase component) and crotapotin (an acidic nontoxic catalytically inactive protein) [95,96]. Villarrubia and coworkers [97] reported that crotoxin has anti-HIV (HIV-1, 2) effect by a direct interaction with Gag p24 glycoprotein on the viral surface, which appears to abrogate the HIV anchoring to host cell.

Furthermore, Muller and colleagues [88] working with diverse sPLA₂s isolated from *C. d. terrificus* venom explored different approaches to unveil the potent antiviral activity mediated by crotoxin, PLA₂-CB and PLA₂-IC against DENV-2 and YFV (enveloped virus). The authors demonstrated that all investigated sPLA₂s promoted a significant inhibition of DENV-2 and YFV entry into VERO E6 cells by a direct action on the viral particles (virucidal activity), and by interfering in the adsorption and internalization steps (early stages of the viral replication cycle) [88]. Besides that, cell pretreatment with three sPLA₂s was able to protect host cell against flaviviruses infection after 7 days by the reduction in the number of plaque formation. Interestingly, sPLA₂s treatment after viral infection promoted an enhancement of load viral, indicating that antiviral effect occurs in the early stages of viral infection [88]. In addition, the researchers gained insights into the role of catalytic sites of the tested sPLA₂s, proposing the use of a sPLA₂ without catalytic activity (BthTX-I) isolated from *Bothrops jararacussu* [98].

BthTX-I revealed antiviral activity against YFV and DENV-2 in the virucidal, adsorption and internalization assays. Interestingly, as shown to other catalytically-active sPLA₂s at 100 ng/μL, BthTX-I at the same concentration was also able to inhibit YFV entry by virucidal activity (100%), interfering in adsorption (77%) and internalization (78%) [88]. Although BthTX-I showed antiviral activity, the effective concentration 50% (EC₅₀) values obtained for this toxin were extremely higher when compared to the catalytically-active sPLA₂s. For example, for the half-maximum virucidal activity against YFV, this toxin required 7.063 ng/μL, while crotoxin, PLA₂-CB and PLA₂-IC demanded 0.00045, 0.0037 and 0.0054 ng/μL, respectively. In a similar way against DENV-2, BthTX-I acted at 4.8 ng/μL, in contrast to the crotoxin, PLA₂-CB and PLA₂-IC that required 0.001, 0.00003 and 0.0137 ng/μL, respectively. As shown, the huge differences of EC₅₀ values between BthTX-I and enzymatically active proteins reflect that the enzymatic activity is an important factor for the antiviral activity of sPLA₂s [88].

In a further study, PLA₂-CB and crotoxin inhibited virus entry by virucidal activity against other enveloped viruses, such as Rocio virus (ROCV; Flaviviridae family), Oropouche virus (OROV; Bunyaviridae family), and Mayaro virus (MAYV; Togaviridae family). However, these compounds did not show virucidal effect against Coxsackie B5 virus (CV-B5; Picornaviridae family; non-enveloped virus), hence suggesting that the possible antiviral action occurs upon the lipid bilayer viral envelope [89]. To corroborate these findings, it was demonstrated that preincubating DENV-2 with PLA₂-CB or crotoxin resulted in an increase of exposure and degradation of viral RNA [89]. Also, Russo and collaborators [99] expressed two recombinant PLA₂-CB isoforms through a prokaryotic system and noted that both rPLA₂-CB1 and rPLA₂-CB2 maintained the viral inhibitory activity against CHIKV, DENV-2, YFV and ZIKV when compared to the native sPLA₂-CB. Additionally, Muller and colleagues [88,89] suggested that the mechanism of action of PLA₂-CB isolated from *C. t. terrificus* against DENV can occur through an interaction with components on the host cell surface or mainly due to the glycerophospholipid cleavage on the virus

envelope, destabilizing viral E proteins and resulting in the viral envelope disruption and RNA viral exposure before the infection of host cells.

In order to gain insights into the antiviral mechanism of sPLA₂s obtained from *C. t. terrificus*, Shimizu and colleagues [90] showed that PLA₂-CB inhibited HCVcc JFH-1 virus strain entry and replication in Huh 7.5 cells, and crotoxin blocked virus entry and release, suggesting that these proteins possess multiple antiviral effects against HCV. Moreover, the authors also reported that PLA₂-CB significantly decrease the levels of lipid droplets, which are essential for the HCV replication complex, and reduced the levels of HCV NS5A protein due to the replication inhibition, evidencing that besides the action on virus entry, PLA₂-CB is able to disrupt HCV replication probably by an interference in lipid metabolism of host cell [90,100,101].

3.2. BIK-PLA₂ and BID-PLA₂ from *Bothrops leucurus* venom

Both BIK-PLA₂ (Lys49 sPLA₂s) and BID-PLA₂ (Asp49 sPLA₂s) are two basic sPLA₂s isolated from *Bothrops leucurus* venom, a pit viper (white-tailed-jararaca) commonly found in the northeast of Brazil [102]. Cecilio and coworkers [91] showed that the pretreatment of LLC-MK2 cells (Rhesus Monkey Kidney Epithelial cells) with each isoform of BI-PLA₂ followed by viral infection was able to inhibit DENV infectivity (serotypes 1, 2 and 3), measured by qRT-PCR quantification of the DENV viral load in the cell supernatants after virus infection. On the other hand, BI-PLA₂s treatment after viral entry was not capable of inhibiting viral replication, then suggesting that the antiviral effect occurs upon components on the surface of the host cell membrane. The authors did not assess the potential virucidal mechanism of BI-PLA₂s against DENV. However, they suggested that the possible mechanism of action of BI-PLA₂s does not depend exclusively on their catalytic site. The Lys49-BIK-PLA₂ treatment was able to interfere in the viral load, indicating that the functional effect mediated by BI-PLA₂s also may occur due to the presence of pharmacological domains on the enzyme surface that would allow the interaction with host cell proteins, as well as the enzymatic activity [91]. The authors hypothesized that the DENV RNA level reduction is mediated by the intracellular action of BI-PLA₂s due to the higher penetrability capacity of basic sPLA₂s, in comparison to neutral and acidic enzymes [91,103].

3.3. Mt-I and Mt-II from *Bothrops asper* venom

Bothrops asper is a viperid specie found in Central America and its venom contains significant concentrations of acid and basic sPLA₂ enzymes [104]. The *B. asper* venom has both the basic enzymatically-active sPLA₂ (Mt-I) and the catalytically-inactive sPLA₂-like protein (Mt-II) [74].

Brenes and collaborators [92] investigated the antiviral potential triggered by both Mt-I and Mt-II isoforms isolated from *B. asper* venom. The authors showed that these sPLA₂s at concentration of 50 μg/mL completely blocked virus entry by a virucidal action against members of Flaviviridae family, such as DENV and YFV, while exhibited moderate to negligible effects against other enveloped viruses (HSV-1, HSV-2, Influenza A H3N2 and Vesicular stomatitis VSV) or non-enveloped viruses (Sabin Poliovirus 1, 2 and 3). Interestingly, for the half-maximum virucidal activity against DENV-2, Mt-I required 1.5 ng/mL, while Mt-II acted at 2768 ng/mL, revealing that Mt-I is extremely more potent than Mt-II [92]. Investigating the role of the enzymatic activity in the inhibitory effect upon DENV-2, it was promoted the inactivation of the catalytic activity of Mt-I with *p*-bromophenacyl bromide (*p*BPB). The data showed that the chemical inactivation of Mt-I resulted in a reduction of the virucidal potency, indicating the relevant role of the enzymatic action against viral infection [92]. Even without enzymatic activity, the C-terminal region of Mt-II, which encompasses the amino acid residues 115–129, is responsible for the membrane-permeabilizing effect caused in many cellular types [67], as well as its bactericidal activity [105]. Notwithstanding that, the authors

demonstrated that, even at high concentrations, the synthetic peptide “p115” corresponding to the C-terminal region of Mt-II (amino acid residues 115–129) did not inhibit DENV-2 [92]. Thus, the authors speculate that the weak virucidal effect of Mt-II may be intrinsic or more possible related to a trace contamination with Mt-I, where the total chromatographic separation for these toxins is hardly achieved [92].

In addition, it was suggested that Mt-I acts by a direct virucidal mechanism that depends on its enzymatic activity, which may hydrolyze viral envelope phospholipids and disrupt the viral envelope of flaviviruses leading to the impairment of the infection. Also, the mode of action of Mt-I and Mt-II is not related to an effect on host cell, since cell treatment after infection did not interfere in viral replication [92]. Furthermore, in a pretreatment assay, it was demonstrated a partial reduction of viral plaques, that may be explained by a slight cytotoxic action of Mt-I on cells [92]. Finally, the higher antiviral activity of Mt-I against Flaviviridae viruses in comparison to other enveloped virus families may be related to the specific structural organization, physicochemical composition, curvature and fluidity of viral envelope from flaviviruses, which may positively affect the catalytic activity of Mt-I against this family [106].

3.4. Taipoxin (*Oxyuranus scutellatus*), nigexine (*Naja nigricollis*) and Nmm_{CMIII} (*Naja mossambica mossambica*)

In a previous study, Fenard and colleagues [107] demonstrated anti-HIV-1 effects of different sPLA₂s from snake venom, such as taipoxin (*Oxyuranus scutellatus* venom), Nmm_{CMIII} (*Naja mossambica mossambica* venom) [108,109] and nigexine (*Naja nigricollis* venom) [110]. Investigating the possible mode of action of some of these sPLA₂s, it was observed that despite their enzymatic activity, Nmm_{CMIII} and taipoxin did not show virucidal effects against HIV-1, but promoted an efficient inhibition of HIV-1 entry by preventing the intracellular release of HIV-1 Gap p24 proteins from the viral capsid [107].

The blockage of HIV entry appears to not depend exclusively on sPLA₂s catalytically active, which was confirmed through two manners: i) the use of inhibitors of sPLA₂s activity, such as phenacyl bromide, aristolochic acid or oleoyloxyethylphosphocholine, that were not able to interfere in the blockage of virus entry mediated by sPLA₂s; ii) the use of cleavage products of sPLA₂s, such as arachidonic acid, lysophosphatidylethanolamine, lysophosphatidic acid, oleoyl-lysophosphatidylcholine and palmitoyl-lysophosphatidylcholine, which were also not able to inhibit virus entry [107]. In addition, competition binding assays between sPLA₂s and host cells showed extremely low dissociation constant (K) values for Nmm_{CMIII}, taipoxin and nigexine, suggesting that the inhibition of HIV-1 entry triggered by sPLA₂s is more probably linked to sPLA₂s binding membrane receptors of host cells than their enzymatic activity [107,111].

3.5. CM-II-sPLA₂ from *Naja mossambica mossambica* venom

CM-II-sPLA₂ is a secreted PLA₂ isoform isolated from *Naja mossambica mossambica* venom [112,113]. Recently, Chen and co-workers [114] reported that this sPLA₂ possesses a potent dose-dependent virucidal activity that impairs the entry of enveloped viruses from budding through the endoplasmic reticulum, such as HCV, DENV and JEV (Japanese encephalitis virus) belonging to the Flaviviridae family. In contrast, CM-II-sPLA₂ demonstrated a low antiviral activity against other enveloped viruses by: i) budding through the plasma membrane, as observed for SINV (Sindbis virus; Togaviridae), SeV (Sendai virus; Paramyxoviridae), FLUAV (Influenza A virus; Orthomyxoviridae), VSNJV (Vesicular stomatitis New Jersey virus; Rhabdoviridae) and HIV-1 (Retroviridae); ii) budding through the trans-Golgi network, as seen for HSV-1 (Herpes simplex virus type 1; Herpesviridae); iii) budding through the ER-Golgi intermediate compartment, as for MERS-CoV (Middle East respiratory syndrome coronavirus; Coronaviridae). Additionally, the slight effect was also observed

against non-enveloped viruses, such as EMCV (Encephalomyocarditis virus; Picornaviridae) and CV-B3 (Coxsackievirus B3; Picornaviridae) [114].

The disruption of viral envelope by CM-II-sPLA₂ appears to be directly related to its enzymatic activity, which was confirmed by the use of manoalide (a specific sPLA₂ inhibitor) that inhibited the virucidal activity of CM-II-sPLA₂ against HCV and DENV [114]. Moreover, the selectivity of CM-II-sPLA₂ for virus buds through endoplasmic reticulum may be related to the differences in the phospholipid contents and physicochemical characteristics (thickness and sturdiness) that can differ among the different routes of viral budding, which would enhance the sensitivity to CM-II-sPLA₂ mediated by hydrolysis against HCV, DENV and JEV [114–117].

4. Proposed antiviral mechanism of sPLA₂s from snake venom

Findings from the current literature about the antiviral activity of toxins (Table 1) are heterogeneous, since authors developed a variety of assays/models using different sPLA₂s and viruses. The virucidal model corresponds to the strategy in which the toxins act directly on the virus particles before infecting the cell monolayer; in the pre-infection model, the uninfected monolayers are previously treated with toxins before viral infection; and in the post-infection model, cell monolayers are adsorbed with the virus followed by toxin treatment. In this sense, many studies raised the following questions: in which stages of virus replication are the sPLA₂s able to interfere? Does the antiviral action of sPLA₂s depend on their catalytic activity? Based on this, we summarize a possible model of antiviral action mediated by sPLA₂s from snake venom.

As discussed above, sPLA₂s have demonstrated to be potent antiviral inhibitors by interfering in different stages of virus replicative cycle as entry steps, replication and release (Fig. 1). Current studies have reported that the antiviral action of sPLA₂s on steps of viral cycle can occur through a direct action upon viral particle and/or by an interaction with virus or host cell components.

Regarding the virucidal activity, studies have shown that both catalytically-active sPLA₂s (crotoxin, PLA₂-IC, PLA₂-CB, Mt-I and CM-II-sPLA₂) and catalytically-inactive sPLA₂s (Mt-II and BthTX-I) indicated virucidal activity preferentially against enveloped viruses, such as DENV (serotypes 1, 2 and 3), YFV, ROCV, OROV, MAYV, HCV, JEV, MERS-CoV, SINV, FLUAV, SeV, VSNJV, HIV-1 and HSV-1 [88–90,92,114].

It is proposed that the potent virucidal activity of sPLA₂s against enveloped viruses is likely associated with the ability that catalytically-active sPLA₂s have to cleave glycerophospholipids in the virus lipid envelope, and it is reasonable to propose that sPLA₂s also present domains that are capable to interact with viral envelope components, which could lead to viral envelope disruption, hence resulting in exposure of the viral content (viral inactivation) and compromising the early stages of viral replication. Additionally, Muller and colleagues [88,89], through a steric and electrostatic analysis of the interaction of PLA₂-CB with the DENV envelope lipid bilayer, showed that PLA₂-CB probably accesses the DENV lipid bilayer through the pores found on each of the twenty 3-fold vertices in the E protein shell on the DENV surface, which would allow the glycerophospholipid cleavage on the virus envelope and destabilization of the E proteins. Interestingly, it has been demonstrated that the structural organization and lipid composition of viral envelope may influence the antiviral efficiency of some sPLA₂s, suggesting that the virucidal mechanism mediated by sPLA₂s is specific [92].

Independent studies have revealed that sPLA₂s such as crotoxin, PLA₂-IC, PLA₂-CB, BI-PLA₂ and BthTX-I are also able to dramatically impact the entry, replication and release of viruses by targeting host cell components [88–91]. To gain insights into these viral cycle stages, it was demonstrated that Nmm_{CMIII}, taipoxin and nigexine prevented the intracellular release of HIV-1 Gap p24 proteins from the viral capsid (inhibition virus entry) by a direct binding to membrane receptors of




Fig. 1. Schematic representation of the mechanisms of action of sPLA₂s from snake venom on viral replicative cycle. sPLA₂s, which possess antiviral activity, are indicated in early and/or late stages of the viral life cycle: entry, replication and release. Mt-I and Mt-II (*Bothrops asper*), BthTX-I (*Bothrops jararacussu*), crotoxin, PLA₂-CB and PLA₂-IC (*Crotalus durissus terrificus*), CM-II-sPLA₂ and Nmm_{CMIII} (*Naja mossambica mossambica*), nigexine (*Naja nigricollis*), taipoxin (*Oxyuranus scutellatus*), BIK-PLA₂ and BID-PLA₂ (*Bothrops leucurus*) are demonstrated.

host cells [107]. In addition, PLA₂-CB was able to disrupt HCV replication probably by an interference in lipid metabolism of host cell [90].

It was demonstrated through the use of both specific sPLA₂ inhibitors and the catalytically-inactive sPLA₂s that the antiviral effect of the major tested catalytically-active sPLA₂s, such as crotoxin, PLA₂-IC, PLA₂-CB, BID-PLA₂, Mt-I and CM-II-sPLA₂ is significantly higher when presented their functional catalytic site to sPLA₂s with no enzymatic activity (BthTX-I, BIK-PLA₂ and Mt-II) [88,91,92,114].

In order to corroborate with the data from the current literature, we performed docking simulations between the sPLA₂s from *Bothrops asper* venom and three phospholipids found in the DENV envelope, which are 1-Palmitoyl-2-oleoylphosphatidylcholine (POPC), 1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE) and 1-Palmitoyl-2-oleoylphosphatidylserine (POPS) [118]. The molecular docking simulations were done by using the 3D crystal structure of Mt-I (PDB: 5TFV) and Mt-II (PDB ID 4YV5) retrieved from Protein Database (<https://www.rcsb.org/>).

We simulated the interaction in the enzymatic site of sPLA₂s with palmitoyl phospholipids (head or complete structure) using AutoDock Vina software [119]. The predicted affinity between sPLA₂s and palmitoyl phospholipids (head or complete) was similar (Table 2).

Table 2
Docking simulations between Mt-I and Mt-II with palmitoyl phospholipids (head or complete structure) from DENV envelope.

PLA ₂ s affinity (kcal/mol)	Phospholipids					
	POPC		POPE		POPS	
	Head	Complete	Head	Complete	Head	Complete
Mt-I	-5.1	-5.4	-4.7	-5.1	-5.0	-5.4
Mt-II	-4.3	-4.5	-4.3	-4.7	-4.3	-4.8

POPC - 1-palmitoyl-2-oleoylphosphatidylcholine; POPE - 1-palmitoyl-2-oleoylphosphatidylethanolamine; POPS - 1-palmitoyl-2-oleoylphosphatidylserine.

Concerning to the interaction with the phospholipids head, Mt-I showed a higher affinity to POPC, POPE and POPS (−5.1, −4.7 and −5.0 kcal/mol, respectively) related to Mt-II (Table 2). When we simulated the docking with the complete palmitoyl phospholipid molecule, Mt-I also has a higher affinity than Mt-II (Table 2).

Although we do not observe a strong difference in the affinity between Mt-I and Mt-II for palmitoyl phospholipids, it is possible to note structural variation in the enzymatic site of these two toxins. Compared to Mt-II, the enzymatic site of Mt-I (Fig. 2A) is more suitable due to a smaller aspartic acid radical group. The van der Waals radii volume of aspartic acid is 91 and hence it is more prominent, while the lysine has a volume of 135, and this results in less space in enzymatic site entrance in Mt-II (Fig. 2B). This difference could create an enzymatic site more restricted to palmitoyl phospholipid entrance/binding and be partially responsible for the absence of enzymatic activity in Mt-II [120]. In addition, the enzymatic activity of Mt-I can be attributed to highly conserved catalytic site formed by the amino acid residues His48, Asp49, Tyr52 and Asp99. Asp49 coordinates the hydrolysis reaction of phospholipids together with the residues of the Ca²⁺ binding loop, essential in the catalytic activity of PLA₂s. The substitution of lysine residue at the same position affects the ability of this protein to bind to Ca²⁺, resulting in the absence of catalytic activity [92].

Despite the stronger antiviral activity is associated with the enzymatic activity, the antiviral mechanism of sPLA₂s does not depend exclusively on their catalytic site, since Lys49 sPLA₂s and inhibited catalytically-active sPLA₂s were also able to show antiviral effects, suggesting that sPLA₂s may possess different mechanisms of action. However, additional studies with different Lys49 from snake venom are required to better characterize the antiviral potential of this protein class.

Functional and structural studies have described that the activity of Lys49 PLA₂s from snake venom toward cell membranes in myotoxic mechanism involves an allosteric transition, and the participation of




Fig. 2. Docking simulations between sPLA₂s and 1-palmitoyl-2-oleoylphosphatidylcholine (POPC). Mt-I (A) and Mt-II (B) are showed as surface and the enzymatic site is colored. The amino acids from the enzymatic site are H48 in red, D49 (Mt-I) or K49 (Mt-II) in blue, and Y52 in green. The POPC is showed as wire structure. The aspartic acid has a smaller volume than lysine, which may result in a less open entrance in Mt-II (panel B) compared with Mt-I (panel A). H: histidine; D: aspartate; K: lysine; Y: tyrosine.

two independent interaction sites with the target membrane [67,72,121–123]. The action of Lys49 PLA₂s is related to a cluster of cationic and hydrophobic/aromatic amino acid residues located at the C-terminal region of this toxin. These two conserved regions in most Lys49-PLA₂s are designed by “cationic membrane-docking site” (MDoS), which are formed by the strictly conserved C-terminal residues (Lys115 and Arg118), eventually aided by other cationic and exposed residues such as Lys20, Lys80, Lys122 and Lys127; and the “hydrophobic membrane-disruption site” (MDiS) formed by residues of Leu121 and Phe125. The key step for protein activation is the binding of a fatty acid at the hydrophobic channel, which leads to allosteric transition and structure stabilization exposing MDoS and MDiS to the membrane, following by the insertion of the MDiS region from both monomers into the target membrane. This penetration disrupts the lipid bilayer, causing alterations in the membrane permeability, highlighted by a prominent influx of ions (*i.e.*, Ca²⁺ and Na⁺), and eventually, irreversible intracellular alterations and cell death [123].

According to myotoxic mechanism of Lys49 PLA₂s from viperid snake venoms, it is proposed that the fatty acids which are important to protein activation may come from membrane phospholipid hydrolysis by catalytic PLA₂s (Asp49), highlighting the synergism between Asp49 PLA₂s and Lys49 PLA₂ in snake envenomation [124]. In this way, the antiviral effects of the Lys49 PLA₂s from snake venom, showed in this review, may be associated to fatty acids from the catalytic activity of cytosolic PLA₂ (cPLA₂) from virus lipid envelope, once it was

demonstrated that enzymatic activity of the cPLA₂ is required for replication of various virus [125–127]. Muller and colleagues [126] showed that the pharmacological inhibition of a cellular phospholipase, cPLA₂, using a specific small-molecule inhibitor, drastically reduces coronavirus RNA synthesis and, as a consequence, protein accumulation and the production of infectious virus progeny. In addition, cPLA₂ activity was shown to be critically involved in the production of infectious progeny of HCV and DENV [128].

5. Concluding remarks: sPLA₂s as a possible useful tool for the development of antiviral compounds

The present review highlighted that PLA₂s from snake venom have become valuable as pharmacological tools and/or therapeutic approaches due to their extremely high specificity and potent activity against microbial infection. Regarding to antiviral properties, we highlighted the following remarks: (i) the antiviral effects of sPLA₂s can be mediated by either a dependent or independent catalytic mechanism; (ii) sPLA₂s-antiviral effects are more evident against enveloped virus; (iii) sPLA₂s promoted the blockage of viral entry into host cells by the direct action on the viral particle, resulting in glycerophospholipids cleavage and destabilization of viral envelope proteins; (iv) the structural organization, physicochemical composition, and the curvature and fluidity of viral envelope may influence in the antiviral efficiency of some sPLA₂s; (v) sPLA₂s promoted the blockage of entry, replication and release of virus probably by the interference on the host cell components.

The structure and function of sPLA₂s from snake venom have been widely explored. Homology studies with sPLA₂s have demonstrated highly conserved regions in these proteins capable of disrupting the integrity of membranes and provoking many pharmacological effects. Despite extensive studies on sPLA₂s in over decades, there is few of them focusing on mechanistic aspects of the antiviral activities and to date are limited to *in vitro* and *in silico* models. It is important to note that these sPLA₂s showed damage effects *in vivo*, such as myotoxicity and inflammation. Thus, further *in vivo* studies for attesting antiviral effects of sPLA₂s need to be addressed to investigate their safety, toxicity and pharmacokinetics. Taken together, new structural and functional studies with sPLA₂s are essential to discover new relevant motifs responsible for the antiviral activities that would allow the future use of these proteins or peptides for the design of antiviral drugs, capable of ensuring more stability and targeting the specific site of action.

Acknowledgements

The authors thank Federal University of Bahia (UFBA), Federal University of Uberlândia (UFU) and the Brazilian funding agencies, CNPq, CAPES, FAPEMIG and PPSUS for providing financial support to this study: PPSUS (SUS0037/2018), FAPEMIG (CBB-APQ-01637-15, CBB-APQ-01401-17, APQ-00587-14 and APQ-03385-18), CAPES (Coordination for the Improvement of Higher Education Personnel – Code 001), Royal Society – Newton Advanced Fellowship (grant reference NA 150195) and National Institute of Science and Technology in Theranostics and Nanobiotechnology INCT-TeraNano-CNPq/CAPES/FAPEMIG, grant numbers CNPq-465669/2014-0.

References

- [1] D. Lugo, P. Krogstad, Enteroviruses in the early 21st century: new manifestations and challenges, *Curr. Opin. Pediatr.* 28 (1) (2016) 107–113.
- [2] K.P. Braaten, M.R. Laufer, Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine, *Rev. Obstet. Gynecol.* 1 (1) (2008) 2–10.
- [3] P.J. Dodd, G.P. Garnett, T.B. Hallett, Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings, *AIDS (London, England)* 24 (5) (2010) 729–735.
- [4] D.M. Koelle, L. Corey, Herpes simplex: insights on pathogenesis and possible vaccines, *Annu. Rev. Med.* 59 (2008) 381–395.

- [5] M.W. Carroll, D.A. Matthews, J.A. Hiscox, M.J. Elmore, G. Pollakis, A. Rambaut, R. Hewson, I. Garcia-Dorival, J.A. Bore, R. Koundouno, S. Abdellati, B. Afrough, J. Aiyepada, P. Akhilomen, D. Asogun, B. Atkinson, M. Badusche, A. Bah, S. Bate, J. Baumann, D. Becker, B. Becker-Ziaja, A. Bocquin, B. Borremans, A. Bosworth, J.P. Boettcher, A. Cannas, F. Carletti, C. Castilletti, S. Clark, F. Colavita, S. Diederich, A. Donatus, S. Duraffour, D. Ehichioya, H. Ellerbrok, M.D. Fernandez-Garcia, A. Fizet, E. Fleischmann, S. Grysesels, A. Hermelink, J. Hinzmann, U. Hopf-Guevara, Y. Ighodalo, L. Jameson, A. Kelterbaum, Z. Kis, S. Kloth, C. Kohl, M. Korva, A. Kraus, E. Kuisma, A. Kurth, B. Liedigk, C.H. Logue, A. Ludtke, P. Maes, J. McCowen, S. Mely, M. Mertens, S. Meschi, B. Meyer, J. Michel, P. Molkenthin, C. Munoz-Fontela, D. Muth, E.N. Newman, D. Ngabo, L. Oestereich, J. Okosun, T. Olorok, R. Omiunu, E. Omomoh, E. Pallasch, B. Palyi, J. Portmann, T. Pottage, C. Pratt, S. Priesnitz, S. Quartu, J. Rappe, J. Repits, M. Richter, M. Rudolf, A. Sachse, K.M. Schmidt, G. Schudt, T. Strecker, R. Thom, S. Thomas, E. Tobin, H. Tolley, J. Trautner, T. Vermoesen, I. Vitoriano, M. Wagner, S. Wolff, C. Yue, M.R. Capobianchi, B. Kretschmer, V. Hall, J.G. Kenny, N.Y. Rickett, G. Dudas, C.E. Coltart, R. Kerber, D. Steer, C. Wright, F. Senyah, S. Keita, P. Drury, B. Diallo, H. de Clerck, M. Van Herp, A. Sprecher, A. Traore, M. Diakite, M.K. Konde, L. Koivogui, N. Magassouba, T. Avsic-Zupanc, A. Nitsche, M. Strasser, G. Ippolito, S. Becker, K. Stoecker, M. Gabriel, H. Raoul, A. Di Caro, R. Wolfel, P. Formenty, S. Gunther, Temporal and spatial analysis of the 2014–2015 Ebola virus outbreak in West Africa, *Nature* 524 (7563) (2015) 97–101.
- [6] J. Heukelbach, C.H. Alencar, A.A. Kelvin, W.K. de Oliveira, L. Pamplona de Goes Cavalcanti, Zika virus outbreak in Brazil, *Journal of infection in developing countries* 10 (2) (2016) 116–120.
- [7] G. Neumann, T. Noda, Y. Kawaoka, Emergence and pandemic potential of swine-origin H1N1 influenza virus, *Nature* 459 (7249) (2009) 931–939.
- [8] N.D. Collins, A.D. Barrett, Live attenuated yellow fever 17D vaccine: a legacy vaccine still controlling outbreaks in modern day, *Curr. Infect. Dis. Rep.* 19 (3) (2017) 14.
- [9] D. Wu, T. Wu, Q. Liu, Z. Yang, The SARS-CoV-2 outbreak: what we know, *Int. J. Infect. Dis.* 94 (2020) 44–48.
- [10] K.F. Smith, M. Goldberg, S. Rosenthal, L. Carlson, J. Chen, C. Chen, S. Ramachandran, Global rise in human infectious disease outbreaks, *J. R. Soc. Interface* 11 (101) (2014), 20140950.
- [11] J.R. Pulliam, Viral host jumps: moving toward a predictive framework, *EcoHealth* 5 (1) (2008) 80–91.
- [12] M. Shi, X.D. Lin, X. Chen, J.H. Tian, L.J. Chen, K. Li, W. Wang, J.S. Eden, J.J. Shen, L. Liu, E.C. Holmes, Y.Z. Zhang, The evolutionary history of vertebrate RNA viruses, *Nature* 556 (7700) (2018) 197–202.
- [13] P. Palese, Influenza: old and new threats, *Nat. Med.* 10 (12 Suppl) (2004) S82–S87.
- [14] F. Krammer, Emerging influenza viruses and the prospect of a universal influenza virus vaccine, *Biotechnol. J.* 10 (5) (2015) 690–701.
- [15] L. Qin, Q. Sun, Y. Wang, K.F. Wu, M. Chen, B.C. Shia, S.Y. Wu, Prediction of Number of Cases of 2019 Novel Coronavirus (COVID-19) Using Social Media Search Index, *vol. 17, 2020* (7).
- [16] S. Bhatt, P.W. Gething, O.J. Brady, J.P. Messina, A.W. Farlow, C.L. Moyes, J.M. Drake, J.S. Brownstein, A.G. Hoen, O. Sankoh, M.F. Myers, D.B. George, T. Jaenisch, G.R. Wint, C.P. Simmons, T.W. Scott, J.J. Farrar, S.I. Hay, The global distribution and burden of dengue, *Nature* 496 (7446) (2013) 504–507.
- [17] D.M. Haig, Subversion and piracy: DNA viruses and immune evasion, *Res. Vet. Sci.* 70 (3) (2001) 205–219.
- [18] W.-S. Ryu, *Antivir. Ther.* (2017) 367–381.
- [19] A. Nanbo, M. Imai, S. Watanabe, T. Noda, K. Takahashi, G. Neumann, P. Halfmann, Y. Kawaoka, Ebola virus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner, *PLoS Pathog.* 6 (9) (2010), e1001121.
- [20] J.A. Thorley, J.A. McKeating, J.Z. Rappoport, Mechanisms of viral entry: sneaking in the front door, *Protoplasma* 244 (1–4) (2010) 15–24.
- [21] P. Aleksandrowicz, A. Marzi, N. Biedenkopf, N. Beiforde, S. Becker, T. Hoenen, H. Feldmann, H.J. Schnittler, Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis, *J. Infect. Dis.* 204 (Suppl. 3) (2011) S957–S967.
- [22] B. Marintcheva, Introduction to Viral Structure, Diversity and Biology, (Parts of this chapter were originally published in Marintcheva B. A box of paradoxes: the fascinating world of viruses. *Bridgeway Rev* 2013;32(2):25–8. http://vc.bridgeway.edu/br_rev/vol32/iss2/8 and are reproduced here with the permission of the editor) 2018 1–26.
- [23] I.A. Rodenhuis-Zybert, J. Wilschut, J.M. Smit, Dengue virus life cycle: viral and host factors modulating infectivity, *Cell. Mol. Life Sci.* 67 (16) (2010) 2773–2786.
- [24] S.H. Kaufmann, M.J. McElrath, D.J. Lewis, G. Del Giudice, Challenges and responses in human vaccine development, *Curr. Opin. Immunol.* 28 (2014) 18–26.
- [25] J.N. Maslow, The cost and challenge of vaccine development for emerging and emergent infectious diseases, *Lancet Glob. Health* 6 (12) (2018) e1266–e1267.
- [26] P. Mohammadi Pour, S. Fakhri, S. Asgary, M.H. Farzaei, J. Echeverria, The signaling pathways, and therapeutic targets of antiviral agents: focusing on the antiviral approaches and clinical perspectives of anthocyanins in the management of viral diseases, *Front. Pharmacol.* 10 (2019) 1207.
- [27] S. Duffy, Why are RNA virus mutation rates so damn high? *PLoS Biol.* 16 (8) (2018), e3000003.
- [28] D.K. Li, R.T. Chung, Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus, *Methods in molecular biology* (Clifton, N.J.) 1911 (2019) 3–32.
- [29] E. Takashita, Influenza polymerase inhibitors: mechanisms of action and resistance, *Cold Spring Harbor perspectives in medicine* (2020) <https://doi.org/10.1101/cshperspect.a038687>.
- [30] A. Carr, D.A. Cooper, Adverse effects of antiretroviral therapy, *Lancet* (London, England) 356 (9239) (2000) 1423–1430.
- [31] K.K. Lai, D.L. Gang, J.K. Zawacki, T.P. Cooley, Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI), *Ann. Intern. Med.* 115 (4) (1991) 283–284.
- [32] V. Montessori, N. Press, M. Harris, L. Akagi, J.S. Montaner, Adverse effects of antiretroviral therapy for HIV infection, *Can. Med. Assoc. J.* 170 (2) (2004) 229–238.
- [33] D.A. Dias, S. Urban, U. Roessner, A historical overview of natural products in drug discovery, *Metabolites* 2 (2) (2012) 303–336.
- [34] G. Brahmachari, Natural Products in Drug Discovery: Impacts and Opportunities – An Assessment, 2011 1–199.
- [35] T. Mohamed Abd El-Aziz, A. Garcia Soares, J.D. Stockand, Snake venoms in drug discovery: valuable therapeutic tools for life saving, *Toxins* 11 (10) (2019).
- [36] R. Schoni, The use of snake venom-derived compounds for new functional diagnostic test kits in the field of haemostasis, *Pathophysiol. Haemost. Thromb.* 34 (4–5) (2005) 234–240.
- [37] M. Millard, S. Odde, N. Neamati, Integrin targeted therapeutics, *Theranostics* 1 (2011) 154–188.
- [38] C.Y. Koh, R.M. Kini, From snake venom toxins to therapeutics—cardiovascular examples, *Toxicol.* 59 (4) (2012) 497–506.
- [39] L.A. Calderon, J.C. Sobrinho, K.D. Zaqueo, A.A. de Moura, A.N. Grabner, M.V. Mazzi, S. Marcussi, A. Nomizo, Antitumoral Activity of Snake Venom Proteins: New Trends in Cancer Therapy, vol. 2014, 2014 203639.
- [40] M.A. Ondetti, N.J. Williams, E.F. Sabo, J. Pluscec, E.R. Weaver, O. Kocy, Angiotensin-converting enzyme inhibitors from the venom of *Bothrops jararaca*. Isolation, elucidation of structure, and synthesis, *Biochemistry* 10 (22) (1971) 4033–4039.
- [41] D.W. Cushman, M.A. Ondetti, History of the design of captopril and related inhibitors of angiotensin converting enzyme, *Hypertension* (Dallas, Tex.: 1979) 17 (4) (1991) 589–592.
- [42] R.M. Scarborough, J.W. Rose, M.A. Hsu, D.R. Phillips, V.A. Fried, A.M. Campbell, L. Nannizzi, I.F. Charo, Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of *Sistrurus m. barbouri*, *J. Biol. Chem.* 266 (15) (1991) 9359–9362.
- [43] Z.R. Gan, R.J. Gould, J.W. Jacobs, P.A. Friedman, M.A. Polokoff, Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, *Echis carinatus*, *J. Biol. Chem.* 263 (36) (1988) 19827–19832.
- [44] C. Funk, J. Gmur, R. Herold, P.W. Straub, Reptilase-R—a new reagent in blood coagulation, *Br. J. Haematol.* 21 (1) (1971) 43–52.
- [45] D.S. Wang, M. Hanamoto, F. Fang, M. Ohba, M. Ishii, F. Kimura, E. Higaki, H. Senga, Defibrinogenating effect of batroxobin (Defibrase) in rats and inhibition of migration of human vascular smooth muscle cells by the plasma of batroxobin-treated rats in vitro, *Atherosclerosis* 156 (1) (2001) 73–80.
- [46] N.C. de Moraes, C.C. Neves Mamede, K.C. Fonseca, M.R. de Queiroz, S.A. Gomes-Filho, N.A. Santos-Filho, C. Bordon Kde, M.E. Beletti, S.V. Sampaio, E.C. Arantes, F. de Oliveira, Isolation and characterization of moojenin, an acid-active, anticoagulant metalloproteinase from *Bothrops moojeni* venom, *Toxicol.* 60 (7) (2012) 1251–1258.
- [47] F. Graziano, R. Maugeri, L. Basile, F. Meccio, D.G. Iacopino, Aulogous fibrin sealant (Vivostat(R)) in the neurosurgical practice: part II: vertebro-spinal procedures, *Surg. Neurol. Int.* 7 (Suppl. 3) (2016) S77–S82.
- [48] H. Waheed, S.F. Moin, M.I. Choudhary, Snake venom: from deadly toxins to life-saving therapeutics, *Curr. Med. Chem.* 24 (17) (2017) 1874–1891.
- [49] P. Bailey, J. Wilce, Venom as a source of useful biologically active molecules, *Emergency medicine (Fremantle, W.A.)* 13 (1) (2001) 28–36.
- [50] A.M. Soares, J.P. Zuliani, Toxins of animal venoms and inhibitors: molecular and biotechnological tools useful to human and animal health, *Curr. Top. Med. Chem.* 19 (21) (2019) 1868–1871.
- [51] E.C. da Mata, C.B. Mourao, M. Rangel, E.F. Schwartz, Antiviral activity of animal venom peptides and related compounds, *The journal of venomous animals and toxins including tropical diseases* 23 (2017) 3.
- [52] R. Meenakshisundaram, S. Sweni, P. Thirumalaikolundusubramanian, Hypothesis of snake and insect venoms against human immunodeficiency virus: a review, *AIDS Res. Ther.* 6 (2009) 25.
- [53] J.E. Burke, E.A. Dennis, Phospholipase A2 biochemistry, *Cardiovasc. Drugs Ther.* 23 (1) (2009) 49–59.
- [54] S.Y. Filkin, A.V. Lipkin, A.N. Fedorov, Phospholipase superfamily: structure, functions, and biotechnological applications, *Biochemistry. Biokhimiia* 85 (Suppl. 1) (2020) S177–s195.
- [55] A. Aloulou, Y.B. Ali, S. Bezzine, Y. Gargouri, M.H. Gelb, Phospholipases: an overview, *Methods in molecular biology* (Clifton, N.J.) 861 (2012) 63–85.
- [56] R.K. Arni, R.J. Ward, Phospholipase A2—a structural review, *Toxicol.* 34 (8) (1996) 827–841.
- [57] R.M. Kini, Excitement ahead: structure, function and mechanism of snake venom phospholipase A2 enzymes, *Toxicol.* 42 (8) (2003) 827–840.
- [58] S.C. Austin, C.D. Funk, Insight into prostaglandin, leukotriene, and other eicosanoid functions using mice with targeted gene disruptions, *Prostaglandins & other lipid mediators* 58 (5–6) (1999) 231–252.
- [59] J.M. Gutierrez, B. Lomonte, Phospholipases A2: unveiling the secrets of a functionally versatile group of snake venom toxins, *Toxicol.* 62 (2013) 27–39.
- [60] J. Boldrin-Franca, C.T. Cologna, M.B. Pucca, K.C. Bordon, F.G. Amorim, F.A. Anjolette, F.A. Cordeiro, G.A. Wiesel, F.A. Cerni, E.L. Pinheiro-Junior, P.Y. Shibao, I.G. Ferreira, I.S. de Oliveira, I.A. Cardoso, E.C. Arantes, Minor snake venom proteins: structure, function and potential applications, *Biochim. Biophys. Acta, Gen. Subj.* 1861 (4) (2017) 824–838.
- [61] C.A. Nicolau, P.C. Carvalho, I.L. Junqueira-de-Azevedo, A. Teixeira-Ferreira, M. Junqueira, J. Perales, A.G. Neves-Ferreira, R.H. Valente, An in-depth snake venom proteopeptidome characterization: benchmarking *Bothrops jararaca*, *J. Proteome* 151 (2017) 214–231.
- [62] R. Mendez, F. Bonilla, M. Sasa, Q. Dwyer, J. Fernandez, B. Lomonte, Proteomic profiling, functional characterization, and immunoneutralization of the venom of

- Porthidium porrasi, a pitviper endemic to Costa Rica, *Acta Trop.* 193 (2019) 113–123.
- [63] R.H. Schaloske, E.A. Dennis, The phospholipase A2 superfamily and its group numbering system, *Biochim. Biophys. Acta* 1761 (11) (2006) 1246–1259.
- [64] D.A. Six, E.A. Dennis, The expanding superfamily of phospholipase A(2) enzymes: classification and characterization, *Biochim. Biophys. Acta* 1488 (1–2) (2000) 1–19.
- [65] J.M. Maraganore, G. Merutka, W. Cho, W. Welches, F.J. Kezdy, R.L. Heinrikson, A new class of phospholipases A2 with lysine in place of aspartate 49. Functional consequences for calcium and substrate binding, *J. Biol. Chem.* 259 (22) (1984) 13839–13843.
- [66] Y. Angulo, B. Lomonte, Biochemistry and toxicology of toxins purified from the venom of the snake *Bothrops asper*, *Toxicol* 54 (7) (2009) 949–957.
- [67] B. Lomonte, J. Rangel, Snake venom Lys49 myotoxins: from phospholipases A(2) to non-enzymatic membrane disruptors, *Toxicol* 60 (4) (2012) 520–530.
- [68] J.F. Wei, X.L. Wei, Q.Y. Chen, T. Huang, L.Y. Qiao, W.Y. Wang, Y.L. Xiong, S.H. He, N49 phospholipase A2, a unique subgroup of snake venom group II phospholipase A2, *Biochim. Biophys. Acta* 1760 (3) (2006) 462–471.
- [69] J. Polgar, E.M. Magnenat, M.C. Peitsch, T.N. Wells, K.J. Clemetson, Asp-49 is not an absolute prerequisite for the enzymic activity of low-M(r) phospholipases A2: purification, characterization and computer modelling of an enzymically active Ser-49 phospholipase A2, ecarpholin S, from the venom of *Echis carinatus* sochureki (saw-scaled viper), *The Biochemical journal* 319 (Pt 3) (1996) 961–968.
- [70] C.L. Ownby, H.S. Selistre de Araujo, S.P. White, J.E. Fletcher, Lysine 49 phospholipase A2 proteins, *Toxicol* 37 (3) (1999) 411–445.
- [71] R.M. Kini, H.J. Evans, A common cytolytic region in myotoxins, hemolysins, cardiotoxins and antibacterial peptides, *Int. J. Pept. Protein Res.* 34 (4) (1989) 277–286.
- [72] C.E. Nunez, Y. Angulo, B. Lomonte, Identification of the myotoxic site of the Lys49 phospholipase A(2) from *Agkistrodon piscivorus piscivorus* snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities, *Toxicol* 39 (10) (2001) 1587–1594.
- [73] A.L. Ambrosio, M.C. Nonato, H.S. de Araujo, R. Armi, R.J. Ward, C.L. Ownby, D.H. de Souza, R.C. Garratt, A molecular mechanism for Lys49-phospholipase A2 activity based on ligand-induced conformational change, *J. Biol. Chem.* 280 (8) (2005) 7326–7335.
- [74] B. Lomonte, Y. Angulo, E. Moreno, Synthetic peptides derived from the C-terminal region of Lys49 phospholipase A2 homologues from viperidae snake venoms: biomimetic activities and potential applications, *Curr. Pharm. Des.* 16 (28) (2010) 3224–3230.
- [75] G. Lambeau, P. Ancian, J.P. Nicolas, S.H. Beiboer, D. Moinier, H. Verheij, M. Lazdunski, Structural elements of secretory phospholipases A2 involved in the binding to M-type receptors, *J. Biol. Chem.* 270 (10) (1995) 5534–5540.
- [76] A. Akalu, A. Cretu, P.C. Brooks, Targeting integrins for the control of tumour angiogenesis, *Expert Opin. Investig. Drugs* 14 (12) (2005) 1475–1486.
- [77] E. Jimenez-Charris, D.S. Lopes, S.N.C. Gimenes, S.C. Teixeira, L. Montealegre-Sanchez, L. Solano-Redondo, L. Fierro-Perez, V.M. Rodrigues Avila, Antitumor potential of PIIans-II, an acidic Asp49-PLA2 from *Porthidium lansbergii lansbergii* snake venom on human cervical carcinoma HeLa cells, *Int. J. Biol. Macromol.* 122 (2019) 1053–1061.
- [78] M.L. Massimino, M. Simonato, B. Spolaore, C. Franchin, G. Arrigoni, O. Marin, L. Monturiol-Gross, J. Fernandez, B. Lomonte, F. Tonello, Cell surface nucleolin interacts with and internalizes *Bothrops asper* Lys49 phospholipase A2 and mediates its toxic activity, *Sci. Rep.* 8 (1) (2018) 10619.
- [79] R.M. Kini, H.J. Evans, A model to explain the pharmacological effects of snake venom phospholipases A2, *Toxicol* 27 (6) (1989) 613–635.
- [80] R. Diniz-Sousa, C.A.S. Caldeira, A.M. Kayano, M.V. Paloschi, D.C. Pimenta, R. Simoes-Silva, A.S. Ferreira, F.B. Zanchi, N.B. Matos, F.P. Grabner, L.A. Calderon, J.P. Zuliani, A.M. Soares, Identification of the molecular determinants of the antibacterial activity of LmutTX, a Lys49 phospholipase A2 homologue isolated from *Lachesis muta muta* snake venom (Linnaeus, 1766), *Basic Clin. Pharmacol. Toxicol.* 122 (4) (2018) 413–423.
- [81] C. Prinholato da Silva, T.R. Costa, R.M. Paiva, A.C. Cintra, D.L. Menaldo, L.M. Antunes, S.V. Sampaio, Antitumor potential of the myotoxin BthTX-I from *Bothrops jararacussu* snake venom: evaluation of cell cycle alterations and death mechanisms induced in tumor cell lines, *The Journal of venomous animals and toxins including tropical diseases* 21 (2015) 44.
- [82] F.V. Azevedo, D.S. Lopes, S.N. Cirilo Gimenes, D.C. Ache, L. Vecchi, P.T. Alves, O. Guimaraes Dde, R.S. Rodrigues, L.R. Goulart, M. Rodrigues Vde, K.A. Yoneyama, Human breast cancer cell death induced by BnSP-6, a Lys-49 PLA(2) homologue from *Bothrops pauloensis* venom, *Int. J. Biol. Macromol.* 82 (2016) 671–677.
- [83] F.V.P. de Vasconcelos Azevedo, M.A.P. Zoia, D.S. Lopes, S.N. Gimenes, L. Vecchi, P.T. Alves, R.S. Rodrigues, A.C.A. Silva, K.A.G. Yoneyama, L.R. Goulart, V. de Melo Rodrigues, Antitumor and antimetastatic effects of PLA2-BthTX-II from *Bothrops jararacussu* venom on human breast cancer cells, *Int. J. Biol. Macromol.* 135 (2019) 261–273.
- [84] A. Bazaa, J. Luis, N. Srairi-Abid, O. Kallech-Ziri, R. Kessentini-Zouari, C. Defilles, J.C. Lissitzky, M. El Ayebe, M. Marrakchi, MVL-PLA2, a phospholipase A2 from *Macrovipera lebetina* transmediterranean venom, inhibits tumor cells adhesion and migration, *Matrix Biol.* 28 (4) (2009) 188–193.
- [85] D.C. Nunes, M.M. Figueira, D.S. Lopes, D.L. De Souza, L.F. Izidoro, E.A. Ferro, M.A. Souza, R.S. Rodrigues, V.M. Rodrigues, K.A. Yoneyama, BnSP-7 toxin, a basic phospholipase A2 from *Bothrops pauloensis* snake venom, interferes with proliferation, ultrastructure and infectivity of *Leishmania (Leishmania) amazonensis*, *Parasitology* 140(7) (2013) 844–854.
- [86] I.P. Borges, L.E. Castanheira, B.F. Barbosa, D.L. de Souza, R.J. da Silva, J.R. Mineo, K.A. Tudini, R.S. Rodrigues, E.A. Ferro, V. de Melo Rodrigues, Anti-parasitic effect on *Toxoplasma gondii* induced by BnSP-7, a Lys49-phospholipase A2 homologue from *Bothrops pauloensis* venom, *Toxicol* 119 (2016) 84–91.
- [87] J.P. Rodrigues, F.V.P. Vasconcelos Azevedo, M.A.P. Zoia, L.P. Maia, L.I.V. Correia, J.M. Costa-Cruz, V. de Melo Rodrigues, L.R. Goulart, The anthelmintic effect on *Strongyloides venezuelensis* induced by BnSP-6, a Lys49-phospholipase A2 homologue from *Bothrops pauloensis* venom, *Curr. Top. Med. Chem.* 19 (22) (2019) 2032–2040.
- [88] V.D. Muller, R.R. Russo, A.C. Cintra, M.A. Sartim, M. Alves-Paiva Rde, L.T. Figueiredo, S.V. Sampaio, V.H. Aquino, Crotoxin and phospholipases A(2) from *Crotalus durissus terrificus* showed antiviral activity against dengue and yellow fever viruses, *Toxicol* 59 (4) (2012) 507–515.
- [89] V.D. Muller, R.O. Soares, N.N. dos Santos Jr., A.C. Trabuco, A.C. Cintra, L.T. Figueiredo, A. Caliri, S.V. Sampaio, V.H. Aquino, Phospholipase A2 isolated from the venom of *Crotalus durissus terrificus* inactivates dengue virus and other enveloped viruses by disrupting the viral envelope, *PLoS One* 9 (11) (2014) e112351.
- [90] J.F. Shimizu, C.M. Pereira, C. Bittar, M.N. Batista, G.R.F. Campos, S. da Silva, A.C.O. Cintra, C. Zothner, M. Harris, S.V. Sampaio, V.H. Aquino, P. Rahal, A.C.G. Jardim, Multiple effects of toxins isolated from *Crotalus durissus terrificus* on the hepatitis C virus life cycle, *PLoS One* 12 (11) (2017) e0187857.
- [91] A.B. Cecilio, S. Caldas, R.A. Oliveira, A.S. Santos, M. Richardson, G.B. Naumann, F.S. Schneider, V.G. Alvarenga, M.I. Estevão-Costa, A.L. Fuly, J.A. Eble, E.F. Sanchez, Molecular characterization of Lys49 and Asp49 phospholipases A₂ from snake venom and their antiviral activities against dengue virus, *Toxins* 5 (10) (2013) 1780–1798.
- [92] H. Brenes, G.D. Loria, B. Lomonte, Potent virucidal activity against Flaviviridae of a group IIA phospholipase A(2) isolated from the venom of *Bothrops asper*, *Biologicals* 63 (2020) 48–52.
- [93] J. Prado-Franceschi, O.V. Brazil, Convulxin, a new toxin from the venom of the South American rattlesnake *Crotalus durissus terrificus*, *Toxicol* 19 (6) (1981) 875–887.
- [94] G. Alexander, J. Grothusen, H. Zepeda, R.J. Schwartzman, Gyroxin, a toxin from the venom of *Crotalus durissus terrificus*, is a thrombin-like enzyme, *Toxicol* 26 (10) (1988) 953–960.
- [95] R.A. Hendon, H. Fraenkel-Conrat, Biological roles of the two components of the crotoxin, *Proc. Natl. Acad. Sci. U. S. A.* 68 (7) (1971) 1560–1563.
- [96] K. Rubsamen, H. Breithaupt, E. Habermann, Biochemistry and pharmacology of the crotoxin complex. I. Subfractionation and recombination of the crotoxin complex, *Naunyn-Schmiedeberg Arch. Pharm. Toxicol.* 270 (3) (1971) 274–288.
- [97] V.G. Villarrubia, L.A. Costa, R.A. Díez, Fosfolipasas A2 segregadas (sPLA2): ¿amigas o enemigas? ¿Actores de la resistencia antibacteriana y antiviral de la inmunodeficiencia humana? *Med. Clin.* 123 (19) (2004) 749–757.
- [98] A.C. Cintra, S. Marangoni, B. Oliveira, J.R. Giglio, Bothropstoxin-I: amino acid sequence and function, *J. Protein Chem.* 12 (1) (1993) 57–64.
- [99] R.R. Russo, N.N. Dos Santos Junior, A.C.O. Cintra, L.T.M. Figueiredo, S.V. Sampaio, V.H. Aquino, Expression, Purification and Virucidal Activity of Two Recombinant Isoforms of Phospholipase A2 From *Crotalus durissus terrificus* Venom, vol. 164, 2019 1159–1171 (4).
- [100] R. Bartschlag, V. Lohmann, F. Penin, The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection, *Nat. Rev. Microbiol.* 11 (7) (2013) 482–496.
- [101] T. Masaki, R. Suzuki, K. Murakami, H. Aizaki, K. Ishii, A. Murayama, T. Date, Y. Matsuura, T. Miyamura, T. Wakita, T. Suzuki, Interaction of hepatitis C virus non-structural protein 5A with core protein is critical for the production of infectious virus particles, *J. Virol.* 82 (16) (2008) 7964–7976.
- [102] D.A. Higuchi, C.M. Barbosa, C. Bincoletto, J.R. Chagas, A. Magalhaes, M. Richardson, E.F. Sanchez, J.B. Pesquero, R.C. Araujo, J.L. Pesquero, Purification and partial characterization of two phospholipases A2 from *Bothrops leucurus* (white-tailed-jararaca) snake venom, *Biochimie* 89 (3) (2007) 319–328.
- [103] T. Chijiwa, E. Tokunaga, R. Ikeda, K. Terada, T. Ogawa, N. Oda-Ueda, S. Hattori, M. Nozaki, M. Ohno, Discovery of novel [Arg49]phospholipase A2 isozymes from *Protobothrops elegans* venom and regional evolution of *Crotalinae* snake venom phospholipase A2 isozymes in the southwestern islands of Japan and Taiwan, *Toxicol* 48 (6) (2006) 672–682.
- [104] A. Alape-Giron, L. Sanz, J. Escolano, M. Flores-Diaz, M. Madrigal, M. Sasa, J.J. Calvete, Snake venomomics of the lancehead pitviper *Bothrops asper*: geographic, individual, and ontogenetic variations, *J. Proteome Res.* 7 (8) (2008) 3556–3571.
- [105] L. Paramo, B. Lomonte, J. Pizarro-Cerda, J.A. Bengoechea, J.P. Gorvel, E. Moreno, Bactericidal activity of Lys49 and Asp49 myotoxic phospholipases A2 from *Bothrops asper* snake venom—synthetic Lys49 myotoxin II-(115–129)-peptide identifies its bactericidal region, *Eur. J. Biochem.* 253 (2) (1998) 452–461.
- [106] O.G. Berg, M.H. Gelb, M.D. Tsai, M.K. Jain, Interfacial enzymology: the secreted phospholipase A(2)-paradigm, *Chem. Rev.* 101 (9) (2001) 2613–2654.
- [107] D. Fenard, G. Lambeau, E. Valentin, J.C. Lefebvre, M. Lazdunski, A. Doglio, Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells, *J. Clin. Invest.* 104 (5) (1999) 611–618.
- [108] G. Lambeau, J. Barhanin, H. Schweitz, J. Qar, M. Lazdunski, Identification and properties of very high affinity brain membrane-binding sites for a neurotoxic phospholipase from the taipan venom, *J. Biol. Chem.* 264 (19) (1989) 11503–11510.
- [109] L. Cupilard, R. Mulherkar, N. Gomez, S. Kadam, E. Valentin, M. Lazdunski, G. Lambeau, Both group IB and group IIA secreted phospholipases A2 are natural ligands of the mouse 180-kDa M-type receptor, *J. Biol. Chem.* 274 (11) (1999) 7043–7051.
- [110] S. Schwetsoff, S. Tsunasawa, F. Sakiyama, A. Menez, Nigexine, a phospholipase A2 from cobra venom with cytotoxic properties not related to esterase activity.

- Purification, amino acid sequence, and biological properties, *J. Biol. Chem.* 264 (22) (1989) 13289–13297.
- [111] G. Lambeau, M. Lazdunski, Receptors for a growing family of secreted phospholipases A₂, *Trends Pharmacol. Sci.* 20 (4) (1999) 162–170.
- [112] F.J. Joubert, Naja mossambica mossambica venom. Purification, some properties and the amino acid sequences of three phospholipases A (CM-I, CM-II and CM-III), *Biochim. Biophys. Acta* 493 (1) (1977) 216–227.
- [113] T. Ahmad, A.J. Lawrence, Purification and activation of phospholipase A₂ isoforms from Naja mossambica mossambica (spitting cobra) venom, *Toxicol.* 31 (10) (1993) 1279–1291.
- [114] M. Chen, C. Aoki-Utsubo, M. Kameoka, Broad-spectrum Antiviral Agents: Secreted Phospholipase A₂ Targets Viral Envelope Lipid Bilayers Derived From the Endoplasmic Reticulum Membrane, vol. 7, 2017 15931 (1).
- [115] H.P. Vacklin, F. Tiberg, G. Fragneto, R.K. Thomas, Phospholipase A₂ hydrolysis of supported phospholipid bilayers: a neutron reflectivity and ellipsometry study, *Biochemistry* 44 (8) (2005) 2811–2821.
- [116] G. van Meer, A.I. de Kroon, Lipid map of the mammalian cell, *J. Cell Sci.* 124 (Pt 1) (2011) 5–8.
- [117] V. Monje-Galvan, J.B. Klauda, Modeling yeast organelle membranes and how lipid diversity influences bilayer properties, *Biochemistry* 54 (45) (2015) 6852–6861.
- [118] Q. Zhang, C. Hunke, Y.H. Yau, V. Seow, S. Lee, L.B. Tanner, X.L. Guan, M.R. Wenk, G. Fibriansah, P.L. Chew, P. Kukkaro, G. Biukovic, P.Y. Shi, S.G. Shochat, G. Grüber, S.M. Lok, The stem region of premembrane protein plays an important role in the virus surface protein rearrangement during dengue maturation, *J. Biol. Chem.* 287 (48) (2012) 40525–40534.
- [119] O. Trott, A.J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, *J. Comput. Chem.* 31 (2) (2010) 455–461.
- [120] P.G. Higgs, A four-column theory for the origin of the genetic code: tracing the evolutionary pathways that gave rise to an optimized code, *Biol. Direct* 4 (2009) 16.
- [121] B. Lomonte, E. Moreno, A. Tarkowski, L.A. Hanson, M. Maccarana, Neutralizing interaction between heparins and myotoxin II, a lysine 49 phospholipase A₂ from Bothrops asper snake venom. Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling, *J. Biol. Chem.* 269 (47) (1994) 29867–29873.
- [122] J.I. dos Santos, A.M. Soares, M.R. Fontes, Comparative structural studies on Lys49-phospholipases A₂ from Bothrops genus reveal their myotoxic site, *J. Struct. Biol.* 167 (2) (2009) 106–116.
- [123] C.A. Fernandes, R.J. Borges, B. Lomonte, M.R. Fontes, A structure-based proposal for a comprehensive myotoxic mechanism of phospholipase A₂-like proteins from viperid snake venoms, *Biochim. Biophys. Acta* 1844 (12) (2014) 2265–2276.
- [124] D. Mora-Obando, J. Fernandez, C. Montecucco, J.M. Gutierrez, B. Lomonte, Synergism between basic Asp49 and Lys49 phospholipase A₂ myotoxins of viperid snake venom in vitro and in vivo, *PLoS One* 9 (10) (2014), e109846.
- [125] R. Vijay, X. Hua, D.K. Meyerholz, Y. Miki, K. Yamamoto, M. Gelb, M. Murakami, S. Perlman, Critical role of phospholipase A₂ group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection, *J. Exp. Med.* 212 (11) (2015) 1851–1868.
- [126] C. Müller, M. Hardt, D. Schwudke, B.W. Neuman, S. Pleschka, J. Ziebuhr, Inhibition of cytosolic phospholipase A₂α impairs an early step of coronavirus replication in cell culture, *J. Virol.* 92 (4) (2018).
- [127] C. Allal, C. Buisson-Brenac, V. Marion, C. Claudel-Renard, T. Faraut, P. Dal Monte, D. Streblov, M. Record, J.L. Davignon, Human cytomegalovirus carries a cell-derived phospholipase A₂ required for infectivity, *J. Virol.* 78 (14) (2004) 7717–7726.
- [128] N. Menzel, W. Fischl, K. Hueging, D. Bankwitz, A. Frentzen, S. Haid, J. Gentsch, L. Kaderali, R. Bartenschlager, T. Pietschmann, MAP-kinase regulated cytosolic phospholipase A₂ activity is essential for production of infectious hepatitis C virus particles, *PLoS Pathog.* 8 (7) (2012), e1002829.